Ongoing HIV transmission following a large outbreak among people who inject drugs in Athens, Greece (2014–20)

Background and Aims The human immunodeficiency virus (HIV) outbreak among people who inject drugs (PWID) in Athens, Greece in 2011–13 was the largest recent epidemic in Europe and North America. We aimed to assess trends in HIV prevalence, drug use and access to prevention among PWID in Athens to es...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Addiction (Abingdon, England) England), 2022-06, Vol.117 (6), p.1670-1682
Hauptverfasser: Roussos, Sotirios, Paraskevis, Dimitrios, Psichogiou, Mina, Kostaki, Evangelia Georgia, Flountzi, Eleni, Angelopoulos, Theodoros, Chaikalis, Savvas, Papadopoulou, Martha, Pavlopoulou, Ioanna D., Malliori, Meni, Hatzitheodorou, Eleni, Pylli, Magdalini, Tsiara, Chrissa, Paraskeva, Dimitra, Beloukas, Apostolos, Kalamitsis, George, Hatzakis, Angelos, Sypsa, Vana
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and Aims The human immunodeficiency virus (HIV) outbreak among people who inject drugs (PWID) in Athens, Greece in 2011–13 was the largest recent epidemic in Europe and North America. We aimed to assess trends in HIV prevalence, drug use and access to prevention among PWID in Athens to estimate HIV incidence and identify risk factors and to explore HIV‐1 dispersal using molecular methods during 2014–20. Methods Two community‐based HIV/hepatitis C programmes on PWID were implemented in 2012–13 (n = 3320) and 2018–20 (n = 1635) through consecutive respondent‐driven sampling (RDS) rounds. PWID were uniquely identified among rounds/programmes. We obtained RDS‐weighted HIV prevalence estimates per round for 2018–20 and compared them to 2012–13. We assessed changes in HIV status, behaviours and access to prevention in PWID participating in both periods. We estimated HIV incidence in a cohort of seronegative PWID as the number of HIV seroconversions/100 person‐years during 2014–20 and used Cox regression to identify associated risk factors. Molecular sequencing and phylogenetic analysis were performed in HIV seroconverters. Results HIV prevalence per round ranged between 12.0 and 16.2% in 2012–13 and 10.7 and 11.3% in 2018–20 with overlapping 95% confidence intervals (95% CI). Among PWID participating in both programmes, HIV prevalence (95% CI) increased from 14.2% (11.7–17.1%) in 2012–13 to 22.0% (19.0–25.3%) in 2018–20 (P 
ISSN:0965-2140
1360-0443
DOI:10.1111/add.15812